Background Durable polymers used for first-generation drug-eluting stents (DES) potentially contribute to persistent inflammation and late DES thrombosis. We report the first in human experience with the rapamycin-eluting biodegradable polymer coated cobalt-chromium FIREHAWK stent with abluminal groove. Methods A total of 21 patients with stable or unstable angina, or prior myocardial infarction, with single de novo native coronary stenoses <30 mm in length in vessel sizes ranging from 2.25 to 4.0 mm were enrolled. The primary endpoint was major adverse cardiac events (MACE) at 30 days defined as the composite of cardiac death, myocardial infarction (Q and non-Q), or ischemia-driven target lesion revascularization. Secondary endpoints include device, lesion, and clinical success rates, 4-month in-stent late lumen loss by quantitative coronary angiography (QCA), proportion of uncovered or malapposed stent struts by optical coherence tomograpphy (OCT) at 4 months, and MACE at 4, 12, 24 and 36-month follow-up. Results Device success was 95.7%, lesion and clinical success was 100.0%. There were no MACE events at 30 days. One patient died of non-cardiac hemorrhagic stroke 5 days after index procedure. At 4 months, in-stent late loss was (0.13±0.18) mm, and complete strut coverage was 96.2% by OCT with 0.1% strut malapposition. At 4-month follow-up there was no additional MACE events, and a single target vessel (non-target lesion) revascularization. Conclusions The FIREHAWK abluminal groove biodegradable polymer rapamycin-eluting stent demonstrated feasibility, safety and efficacy in this first in human experience. OCT findings indicated excellent stent strut coverage 4 months after implantation. Larger studies are required to confirm whether the early FIREHAWK stent results translate into longer term restenosis and thrombosis benefits.
rug-eluting stents (DES) have markedly reduced the rate of in-stent restenosis compared with bare-metal stents (BMS), resulting in a significant reduction in repeat revascularizations. 1, 2 However, enthusiasm for this technology has been dampened by concerns about late stent thrombosis (LST), an event often associated with morbid complications. 3, 4 Pathological autopsy studies suggested delayed endothelialization is one of the causes leading to DES thrombosis. Localized hypersensitivity reactions to the durable polymer coating and/or to the drug itself may also add to stent thrombosis. [5] [6] [7] [8] A biodegradable polylactic acid (PLA) polymer with sustained drug release was employed in the FIREHAWK stent (Microport Medical, Shanghai, China) to maintain high tissue concentration of rapamycin. In the ex vivo porcine model, at 4 weeks, FIREHAWK stents exhibited the same level of neointimal proliferation reduction compared with FIREBIRD2 stents, and tended to limit neointimal proliferation in comparison with bare cobalt-chromium alloy stent (average neointimal thickness: FIREHAWK, (0.15±0.10) mm; FIREBIRD2, (0.14±0.06) mm; BMS, (0.20±0.13) mm; P=0.06). During the long-term follow-up up to 52 weeks after FIREHAWK stents' implantation, no "late catch-up" phenomenon was observed (average neointimal thickness: 4 weeks, (0.15±0.10) mm; 12 weeks, (0.16±0.28) mm; 26 weeks, (0.18±0.04) mm; 52 weeks, (0.16±0.05) mm, P >0.05). Histological examination of artery sections taken from animals treated with FIREHAWK stents from 1 week to 52 weeks post implantation have revealed an absence of notable local pathologic hurts including thrombosis, medial hemorrhage, medial necrosis, lack of re-endotheliazation. Regarding the PLA polymer with sustained rapamycin drug membrane biodegradation, the ex vivo method showed nearly 75% of the drug is eluted in 30 days. This polymer coating is fully absorbable and may minimize adverse effect, such as possible hypersensitivity reactions, caused by the permanent presence of a durable polymer. The abluminal groove design of the FIREHAWK stent allows for reduced drug concentration compared with previous generation FIREBIRD and FIREBIRD 2 stents. Although this new FIREHAWK stent had showed good re-endothelialization and reduction of neointimal thickening in a porcine model, it has yet to be confirmed in human. The objective of this first-in-man (FIM) study was to test the safety and feasibility of the FIREHAWK stent to treat de novo coronary lesions.
METHODS

Study design and patient selection
From December 2009 through January 2010, patients were eligible for enrollment in the trial if they were over 18 years of age, had stable, unstable angina or previous myocardial infarction (>1 month prior), with a single de novo native coronary artery stenosis undergoing clinically indicated percutaneous coronary intervention (PCI). Target lesions with a reference diameter of 2.25 and 4.0 mm and lesion length <30 mm were included allowing for protocol mandated single stent placement, with additional investigational stents implanted only for edge dissection, abrupt closure or inadequate lesion coverage. Patients presenting with acute myocardial infarction (AMI) within 1 month, chronic total occlusion with TIMI 0 flow, left ventricular ejection fraction <40%, previous target site stent implantation within 1 year, severe tortuosity, calcification prohibiting full balloon expansion during predilation, bifurcation lesion involving a side branch >2.5 mm in diameter, ostial, graft, and left main lesions were excluded.
All patients were treated with the FIREHAWK stent. The FIREHAWK stent is pre-mounted on a rapid-exchange delivery system, and comprises three components: a cobalt-chromium L605 platform, PLA polymer and rapamycin. Three structures are designed to meet the different diameter of the vessels (Table 1) . Abluminal grooves are scored into the outer surface of the struts, and the rapamycin and PLA polymer complex is poured into the grooves and applied to the outer surface of the stent (Figure 1) . A finite element analysis ( Figure  2) shows that during stent expansion, the stresses and deformations are only focused on the hinge points of the stent, and other stent elements remain unstressed ( Figure  1 ). The average rapamycin dosage of the FIREHAWK stent is 3 μg/mm stent lengths, representing approximately 1/3 of the dose of the FIREBIRD 2 stent.
All enrolled patients received aspirin (300 mg/d for 3 months and 100 mg/d for ever) and clopidogrel (300 mg loading dose one day before the procedure and 75 mg/d for 12 months). Patients underwent protocol mandated clinical follow-up at 1, 4, 9, 13, 24, 36 months and coronary angiography and optical coherence tomography (OCT) follow-up at 4 months. Patients were advised to do 13 months coronary angiography follow-up. The protocol was approved by the institutional review board at Fu Wai Hospital (Beijing, China), and all patients had to provide written informed consent.
Study endpoints
The primary endpoint was major adverse cardiac events (MACE) at 30-day defined as the composite of cardiac death, myocardial infarction (Q and non-Q), and ischemia-driven target lesion revascularization. Ischemia driven revascularization required (1) ischemic symptoms and/or an abnormal functional study and a >50% coronary stenosis by quantitative angiography; or (2) any revascularization for a >70% diameter stenosis. Secondary endpoints included: device success, defined as a diameter stenosis of <30% attained with the FIREHAWK device in the absence of device malfunctions; lesion success, defined as a final diameter stenosis <30% with any device, and clinical success, defined as a final diameter stenosis <30% in the absence of MACE. Other secondary clinical endpoints included MACE at 4, 13, 24 and 36 months. In-stent late lumen loss was measured as 4-month and 13-month by independent quantitative coronary angiography (QCA), as was the proportion of uncovered or malapposed stent struts measured by OCT at 4-month follow-up.
QCA QCA analyses were performed by an independent angiographic core laboratory (China Cardiovascular Research Foundation, Beijing, China) using the QAngio XA analysis software (Medis Medical Imaging System Inc. Leiden, Netherlands). Standard QCA methodology was used including analysis of the stent and the peri-stent segments defined by 5 mm proximal and distal to the stent edge. Binary restenosis was defined in every segment (proximal, distal, and stent) as a >50% diameter stenosis at follow-up. Late lumen loss was defined as the difference between the post-procedure and follow-up minimal lumen diameter.
OCT
OCT was performed at 4-month follow-up using the Model M2 Cardiology Imaging System and ImageWire 0.3556 mm (0.014 inch) wire-type imaging catheter (LightLab Imaging, Westford, Massachusetts, USA) in all cases. To clear blood from the imaging site, the proximal occlusion balloon (Helios TM , LightLab Imaging) was inflated to 50.66 kPa (0.5 atm) and lactated Ringer's solution was infused into the coronary artery from the distal tip of the occlusion balloon at 1.2-2.0 ml/s. The entire length of the stent was imaged with an automatic pullback device acquired at 2 mm/s. All OCT frames were digitally stored and cross-sectional OCT images were analyzed at 0.3 mm intervals (every 3 frames) by independent core laboratory (China Cardiovascular Research Foundation, Beijing, China) using validated software (Medis Medical Imaging System Inc. Leiden). OCT parameters were calculated and defined as follows: neointimal thickness was measured as the perpendicular distance between the endoluminal surfaces of the neointima to the stent strut. Absence of definite neointima over the stent strut was defined as an uncovered stent strut. Distances between the inner surface of the strut reflection and the vessel wall were measured by extending contours of the walls on the outside of the strut shadow. The position of the stent strut on the vessel wall was measured by magnifying the individual stent strut to maximize accuracy when the strut was not fully attached to the vessel wall as determined by visual assessment. Stent strut malapposition was defined as struts with detachment from the vessel wall >110 μm. Stent struts located at bifurcations of major side branches (>2.0 mm in diameter) were excluded from analysis. Thrombus was defined as an irregular mass protruding into the lumen or intraluminal mass with signal-free shadowing unconnected to the luminal surface.
Statistical analysis
Continuous variables are presented as mean ± standard deviation, and categorical variables are presented as counts and percentages. Paired comparisons between post-procedure and 4-and 13-month follow-up were done by a Wilcoxon's signed rank test. All statistical tests were two-tailed and a P value of 0.05 was considered as statistically significant. The current study is a FIM single-arm study, and was designed to provide preliminary hypothesis-generating observations for further studies. The sample size was not defined on the basis of an endpoint hypothesis but rather to provide some information about feasibility, efficacy and safety of the device. Statistical analysis was performed with SAS 8.2 (SAS Institute Inc., NC, USA).
RESULTS
A total of twenty-one patients were enrolled. Baseline clinical characteristics are presented in Table 2 and are representative of the patient population. Device success was achieved in 95.7%; in one patient the FIREHAWK stent did not fully expand resulting in a residual stenosis >30% immediately after stenting. With post-dilation, the under-expansion was solved without residual stenosis. Lesion and clinical success rates were both 100.0%. MACE events are listed in Table 3 . A single patient died of hemorrhagic stroke 5 days after index procedure, and two patients required ischemia-driven target vessel (non-target lesion) revascularization, 123 and 365 days after index procedure. Based on the protocol, these events were not included in the MACE definition. Thus 30-day, 4-and 13-month MACE rates were 0. 
QCA analysis
Procedural angiographic characteristics are presented in Table 2 . Target lesion reference vessel diameter was (2.88±0.51) mm, lesion length was (17.7±6.1) mm, and 62% were complex lesions (American College of Cardiology/American Heart Association (ACC/AHA) lesion complexity B2/C). Angiographic follow-up at 4 and 13 months was obtained in 19 patients (19/20) . Aside from loss to follow-up from the single non-cardiac death, the second patient was asymptomatic but refused to undergo follow-up angiography. These results are presented in Table 4 and Figure 3 . Stent late lumen loss was (0.13±0.18) mm and (0.16±0.07) mm in 4 and 13 months, the difference of 4 and 13 months was (0.07±0.06) mm (P >0.05), and there was no target lesion restenosis.
OCT analysis
OCT follow-up was achieved in 14 patients. Aside from the two patients who did not undergo angiographic follow-up, the other five patients had several reasons for inadequate OCT imaging. Two patients had very large proximal right coronary artery (RCA) segment, and the OCT balloon could not fully occlude the vessel resulting in artifact. Three patients had near left anterior descending (LAD) and left circumflex coronary artery (LCX) ostial stent placement prohibiting safe positioning of the OCT balloon. A total of 1155 image sections were acquired, of which 1084 image sections (96.0%) were analyzable in this study. OCT analysis results are presented in Table 5 and Figure 4 . The mean neointimal area was (7.82±5.20)% and neointimal thickness was (0.064±0.055) mm. The noncovered struts rate was 3.8% and 0.1% struts had mal-apposition. The noncovered/total stent struts ratio >0.3 was found in 2% of cross sections.
DISCUSSION
The efficacy of rapamycin in inhibiting neointimal proliferation has been demonstrated in several clinical studies.
1,2 But the concern for the long-term safety of the first generation of DES remains, especially with respect to risk of LST and very LST (beyond 1 year) . 3, 4 The rationale behind biodegradable polymer-coated stents is that it may improve safety outcomes if the coating is temporary and can degrade gradually and without inflammatory side-effects as the drug elutes, such that both drug and polymer disappear from the arterial wall once the full anti-restenotic effect is achieved and the stented vessel is healed. In a porcine overstretched stent restenosis model, the rapamycin-eluting biodegradable polymer-coated FIREHAWK stent significantly inhibited smooth muscle cell proliferation without obvious delayed vessel wall healing and demonstrated equivalent efficacy compared with the permanent polymer rapamycin stent (data on file at Microport Inc., Shanghai, China). To minimize rapamycin drug concentrations in the vessel, a proprietary fully absorbable composite coating of rapamycin and PLA polymer matrix applied to the abluminal surface with a groove facing the vessel wall was developed for the FIREHAWK stent platform. This unique design enables lower rapamycin drug concentration by targeting the vessel wall with the goal of minimizing long-term inflammation and decreasing stent thrombosis rate, while maintaining anti-restenotic effect.
The FIREHAWK FIM study demonstrates the feasibility and early clinical safety and efficacy of this design 13 months following implant. Only 3 adverse events (14.4%) unrelated to the device occurred at the 13-month follow-up, including one death caused by hemorrhagic stroke and two non-target lesion revascularization. There were no device related MACE with the FIREHAWK; results comparable to other biodegradable polymer DES. 9, 10 The abluminal groove of the FIREHAWK stent directed to the vessel wall, differs from the NEVO Binary in-stent and in-segment restenosis with FIREHAWK were 0 at 4 and 13 months, comparable to permanent polymer-coated rapamycin stents. 12 The mean in-stent ((0.13±0.18) mm, (0.16±0.07) mm) and in-segment ((0.08±0.13) mm, (0.17±0.25) mm) late loss at 4, 13 months are low, as is the standard deviation of the late loss measures, suggesting at least in this small cohort a consistent efficacy measure similar to that observed with rapamycin-eluting stents with permanent polymer, and lower than that seen with paclitaxel eluting stent (PES), zotarolimus-eluting stents and BMS. [13] [14] [15] [16] The difference of minimal lumen diameter between 4 and 13 months was (0.07±0.06) mm, showing no late "catch up" phenomena was observed with the FIREHAWK stent.
Compared with FIRBIRD and FIRBIRD 2 stent, the in-stent late loss distribution of the FIREHAWK is more focal ranging from 0.04 to 0.13 mm (in-stent late lumen loss standard deviation 0.18 mm), compared to the FIREBIRD (range of 0.04 to 0.20 mm; in-stent late lumen loss standard deviation 0.24 mm) (unpublished data from a randomized trial of PROSTENT biodegradable polymer vs. FIREBIRD durable polymer rapamycin-eluting stent: clinicaltrial.gov Identifier 00887211), and the FIRBIRD 2 stent (range of -0.01 to 0.11 mm; in-stent late lumen loss standard deviation 0.09 mm), which demonstrated some positive remodeling with in-stent late loss less than 0 mm. 17 The angiographic data are consistent with the early OCT findings. The FIREHAWK stent had near complete vessel healing with evidence of stent strut coverage in 96.2% of struts at 4 months and a very low rate of stent strut malapposition (0.1%). Several small studies have been recently published addressing the application of OCT for in vivo detection of vessel healing at different follow-up intervals following DES implantation. Matsumoto et al 18 reported 6-month OCT results of 34 patients after rapamycin-eluting stent implantation. Mean neointimal hyperplasia (NIH) thickness was 52.5 μm with 89% complete strut coverage. The FIREHAWK stent showed a thicker neointimal hyperplasia of (64±55) μm comparing favorably with sirolimus-eluting stent (SES), but thinner than PES and BMS. 19 In addition, 99% of stent struts were apposed to the vessel wall and more than 90% (96.2%) were well covered with neointima. The extent of neointimal coverage was less than that of BMS (99%), but better than that of PES (92.6%) and SES (85.8%). 19, 20 Recent pathology based research established the link between incomplete stent strut neointimal coverage and the risk of stent thrombosis. In particular, Finn et al 21 demonstrated that the most powerful predictor of LST is the ratio of noncovered/total stent struts >0.3. In the FIREHAWK FIM study, stent strut coverage was high (96.2%) and only 2% of cross sections had noncovered/total stent struts ratio >0.3. As this parameter is derived from histological data, clinical validation will be required to confirm the predictability of late thrombosis using OCT as the measurement surrogate. Although OCT is increasingly used to quantify stent strut coverage to stratify risk of LST, OCT has yet to be validated as a surrogate of LST, due mainly to the low frequency of LST. Lack of neointimal coverage has been associated with mural thrombus; however, uncovered struts cannot yet be definitively identified as a risk factor of LST, and large scale longitudinal studies correlating intimal coverage of DES and late thrombosis are needed.
The LEADERS trial showed improved strut coverage of the biolimus-eluting stent (BES) using a biodegradable polymer compared with the durable polymer based SES Cypher Select stent, and a recent sub-group analysis showed a reduced cardiac mortality in patients with high Syntax scores compared with the SES Cypher Select group. 22 In contrast, a recent randomized study of 2603 patients compared a biodegradable rapamycin-eluting stent with a permanent polymer DES (Cypher or Xience), and did not show any difference in MACE, including stent thrombosis, at 1 year. 23 These negative findings may be related to the very low 1 year target lesion revascularization rate (2.5%) and stent thrombosis rate (0.29%) with second generation DES such as Xience V. 24 These favorable results are likely related in large part to the significantly lower drug concentration compared with the first generation DES, despite using a permanent polymer. The FIREHAWK stent by design combines a biodegradable polymer and significantly lower drug concentrations providing significant advantage compared with both the first and second generation DES.
The FIREHAWK FIM trial is the initial China State of Food and Drug Administration regulatory trial, providing the preliminary safety and efficacy data required as a requisite to the ongoing pivotal randomized trial comparing the FIREHAWK to the Xience V stent at 15 cardiac centers in China (TARGET I trial, clinicaltrials.gov Identifier: 01196819).
The FIREHAWK FIM was a single-center trial of only 21 patients with standard-risk lesions, representing the FIH feasibility and effectiveness assessment of this novel device. Angiographic follow-up was 95% and OCT was 70%. While late lumen loss is a well validated and accepted surrogate of target lesion revascularization, OCT measures are not currently validated, however do provide some mechanistic insight. These data provide initial evidence for the proof of concept (feasibility, safety and efficacy) of this new DES platform and serves as the rationale for a larger multicenter randomized approval study in more complex lesions and long-term follow-up.
